10
Clinical Trials associated with WXFL10030390A Phase II Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations
The goal of this clinical trial is to evaluate the safety and preliminary efficacy of WX390 combined with Toripalimab in patients with advanced Gastric-type Endocervical Adenocarcinoma with STK11 mutations. The main questions it aims to answer are:
Pharmacokinetic (PK) characteristics of WX390 combined with Toripalimab treatment.
Safety and preliminary in combined therapy. Participants will be treated with WX390 orally and Toripalimab intravenously, and follow the efficacy and safety evaluation according to the protocol.
A Phase Ib/IIa Study to Evaluate the Safety and Preliminary Efficacy of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors
The goal of this clinical trial is to evaluate the safety and preliminary efficacy of WX390 combined with Toripalimab in patients with advanced solid tumors. The main questions it aims to answer are:
the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of WX390;
safety and preliminary in combined therapy. Participants will be treated with WX390 orally and Toripalimab intravenously, and follow the efficacy and safety evaluation according to the protocol.
评估WXFL10030390片联合特瑞普利单抗在晚期实体瘤、淋巴瘤患者中安全性、耐受性和初步疗效的临床试验
[Translation] A clinical trial to evaluate the safety, tolerability and preliminary efficacy of WXFL10030390 tablets combined with toripalimab in patients with advanced solid tumors and lymphomas
评价WXFL10030390片联合特瑞普利单抗治疗晚期实体瘤的剂量限制性毒性(DLT),确定联合治疗中WXFL10030390片最大耐受剂量(MTD)和 II 期推荐剂量(RP2D)
[Translation] To evaluate the dose-limiting toxicity (DLT) of WXFL10030390 tablets combined with toripalimab in the treatment of advanced solid tumors, and to determine the maximum tolerated dose (MTD) and phase II recommended dose (RP2D) of WXFL10030390 tablets in combination therapy
100 Clinical Results associated with WXFL10030390
100 Translational Medicine associated with WXFL10030390
100 Patents (Medical) associated with WXFL10030390
100 Deals associated with WXFL10030390